➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Merck
McKesson
Moodys
Baxter

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,750,726


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,750,726
Title:Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Inventor(s): Baker; Darrell (Middlesex, GB), Bruce; Mark (Stevenage, GB), Crater; Glenn (Mississauga, CA), Noga; Brian (Durham, NC), Thomas; Marian (Ware, GB), Wire; Patrick (Durham, NC)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:14/970,945
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 9,750,726

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline ANORO ELLIPTA umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 203975-001 Dec 18, 2013 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Glaxosmithkline TRELEGY ELLIPTA fluticasone furoate; umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 209482-001 Sep 18, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Glaxosmithkline TRELEGY ELLIPTA fluticasone furoate; umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 209482-002 Sep 9, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,750,726

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0921075.8Dec 1, 2009

International Family Members for US Patent 9,750,726

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010326798 ⤷  Free Forever Trial
Australia 2014204459 ⤷  Free Forever Trial
Australia 2016262698 ⤷  Free Forever Trial
Australia 2018282427 ⤷  Free Forever Trial
Brazil 112012012925 ⤷  Free Forever Trial
Canada 2781487 ⤷  Free Forever Trial
Chile 2012001432 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Moodys
Express Scripts
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.